SY23-3 Clinical development of PARP inhibitors in ovarian cancer

Abstract

Initial clinical development of PARP inhibitor (PARPi) started for ovarian patients with germline BRCA mutation (gBRCAm) based on the mechanistic assumptions. The first large phase 3 trial, SOLO2, focused on the patient with platinum-sensitive recurrent ovarian cancer known to have gBRCAm. On the other hand, the NOVA trial tested the innovative study design. The investigators challenged to include patients with not only gBRCAm but also with non-gBRCAm, which included HRD+ (tBRCAm only and BRCAwt) and HRD-negative population.